NASD · Healthcare · Biotechnology · USA
Edgewise Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Edgewise Therapeutics discovers and develops small molecule medicines for muscle diseases. The company has product candidates in clinical trials for muscular dystrophies and cardiomyopathy, and preclinical programs for additional muscle conditions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Edgewise Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on EWTX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.